Compositions and methods for identifying drug resistant tuberculosis

• US 10,526,664 B2
• Filed: 07/13/2016
• Issued: 01/07/2020
• Est. Priority Date: 07/14/2015
• Status: Active Grant

• Current Assignee: Abbott Molecular Incorporated (Abbott Laboratories)
• Original Assignee: Abbott Molecular Incorporated (Abbott Laboratories)
• Inventors: Wang, Hong, Leckie, Gregor W., Pahalawatta, Vihanga, Abravaya, Klara, Kostera, Joshua, Tang, Ning, Frank, Andrea
• Primary Examiner(s): Benzion, Gary
• Assistant Examiner(s): Oyeyemi, Olayinka A
• Application Number:
  US15/209,453
• Publication Number:
  US 20170044594A1
• Time in Patent Office: 1,273 Days
• Field of Search: None
• CPC Class Codes: A61P 31/06 for tuberculosis
• CPC Class Codes: C12N 1/205 Bacterial isolates
• CPC Class Codes: C12Q 1/689 for bacteria
• CPC Class Codes: C12Q 2600/106 Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12R 2001/32 Mycobacterium

Abstract

Provided herein are compositions and methods for diagnosing and characterizing tuberculosis infection. In particular, provided herein are compositions and methods for identifying drug resistant tuberculosis.

Claims

1. A method of detecting the presence and antibiotic resistance of Mycobacterium complex (MTB) in a subject, comprising:

a) contacting a sample from said subject with first reagents for detecting the presence of MTB wherein said first reagents comprise primer SEQ ID NOs;

22-25, probe SEQ ID NOs;

26 and 27, and a first activation reagent comprising MgCl2, Tris, KCl, Proclin 950, sodium azide and ultrapure water;

b) performing an MTB detection assay with said first reagents, comprising;

i) amplifying said sample from said subject with SEQ ID NO;

22 and SEQ ID NO;

23 to generate an IS6110 amplicon using PCR cycling conditions;

ii) detecting said IS6110 amplicon with SEQ ID NO;

26;

iii) amplifying said sample from said subject with SEQ ID NO;

24 and 25 to generate a PAB amplicon using PCR cycling conditions;

iv) detecting said PAB amplicon with SEQ ID NO;

27; and

c) contacting a sample from said subject with second reagents for detecting the presence of MTB rifampicin and isoniazid resistance genes wherein said second reagents comprise primer SEQ ID NOs;

1-6, probe SEQ ID NOs;

7-18, and a second activation reagent comprising MgCl2, Tris, KCl, Proclin 950, sodium azide and ultrapure water; and

d) performing a rifampicin and isoniazid resistance assay with said second reagents, comprising;

i) amplifying said sample from said subject with SEQ ID NO;

1 and SEQ ID NO;

2 to generate a rpoB RRDR amplicon using PCR cycling conditions;

ii) detecting said rpoB RRDR amplicon with SEQ ID NOs;

7-14;

iii) amplifying said sample from said subject with SEQ ID NO;

3 and SEQ ID NO;

4 to generate a katG amplicon using PCR cycling conditions;

iv) detecting said katG amplicon with SEQ ID NOs;

15 and 16;

v) amplifying said sample from said subject with SEQ ID NO;

5 and SEQ ID NO;

6 to generate an inhA upper stream promoter amplicon using PCR cycling conditions; and

vi) detecting said inhA upper stream promoter amplicon using SEQ ID NOs;

17 and 18; and

wherein said first activation reagent and said second activation reagent are the same activation reagents, and wherein said PCR cycling conditions are the same PCR cycling conditions.

2. The method of claim 1, wherein said amplifying is real time PCR.

3. The method of claim 1, wherein said rifampicin and isoniazid resistance detection assay detects mutations in one or more target regions selected from the group consisting of rpoB RRDR, katG and inhA upper stream promoter.

4. The method of claim 3, wherein said mutations in rpoB are at one or more amino acids selected from the group consisting of D516V, H526Y, H526D, and S531L.

5. The method of claim 3, wherein said katG mutation is amino acid change S315T1 and said inhA upper stream promoter mutation is the nucleic acid mutation C-15T.

6. The method of claim 1, wherein said sample is selected from the group consisting of sputum, BAL, and a NALC sediment of sputum and BAL.

7. The method of claim 1, wherein said MTB is one or more species of Mycobacterium selected from the group consisting of Mycobacterium tuberculosis, Mycobacterium africanum, Mycobacterium bovis, Mycobacterium bovis BCG, Mycobacterium canettii, Mycobacterium microti, Mycobacterium caprae, and Mycobacterium pinnipedii.

8. The method of claim 1, further comprising the step of diagnosing infection by MTB in said subject based on the results of said MTB detection assay.

9. The method of claim 1, further comprising the step of identifying said MTB as resistant to rifampicin and/or isoniazid based on said rifampicin and isoniazid resistance detection assay.

10. A method of detecting the antibiotic resistance of Mycobacterium complex (MTB) in a subject, comprising:

a) contacting a sample from said subject with reagents for detecting the presence of MTB rifampicin and isoniazid resistance genes wherein said reagents comprise primer SEQ ID NOs;

1-6, probe SEQ ID NOs;

7-18, and an activation reagent comprising MgCl2, Tris, KCl, Proclin 950, sodium azide and ultrapure water; and

b) performing a rifampicin and isoniazid resistance assay with said reagents, comprising;

i) amplifying said sample from said subject with SEQ ID NO;

1 and SEQ ID NO;

2 to generate a rpoB RRDR amplicon using PCR cycling conditions;

ii) detecting said rpoB RRDR amplicon with SEQ ID NOs;

7-14;

iii) amplifying said sample from said subject with SEQ ID NO;

3 and SEQ ID NO;

4 to generate a katG amplicon using PCR cycling conditions;

iv) detecting said katG amplicon with SEQ ID NOs;

15 and 16;

v) amplifying said sample from said subject with SEQ ID NO;

5 and SEQ ID NO;

6 to generate an inhA upper stream promoter amplicon using PCR cycling conditions; and

vi) detecting said inhA upper stream promoter amplicon using SEQ ID NOs;

17 and 18; and

wherein said PCR cycling conditions are the same PCR cycling conditions.